NCT04783766

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CK-3773274 in Healthy Chinese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Corxel Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4. Determine the effect of doses of CK-3773274 on the pumping function of the heart. 5. Evaluate the effect CYP2D6 genetic polymorphisms on how the body metabolizes CK-3773274.

Conditions

• Obstructive Hypertrophic Cardiomyopathy
• Healthy Adult Subjects

Interventions

Type	Name	Description
DRUG	CK-3773274	CK-3773274- Tablets
DRUG	Placebo	Placebo- Tablets

Timeline

• Start date: 2021-04-10
• Primary completion: 2021-08-05
• Completion: 2021-08-05
• First posted: 2021-03-05
• Last updated: 2025-01-24

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study